Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
Today’s deal will see the companies take a triple combination into clinical trials.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.